{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:41Z","timestamp":1792172501291,"version":"4.4.0"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T00:00:00Z","timestamp":1647734400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Biomedical Research Centre","award":["IS-BRC-1215-20021"],"award-info":[{"award-number":["IS-BRC-1215-20021"]}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["CM48 and CM444"],"award-info":[{"award-number":["CM48 and CM444"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004682","name":"Oracle","doi-asserted-by":"publisher","award":["ORC 22-ICR0920"],"award-info":[{"award-number":["ORC 22-ICR0920"]}],"id":[{"id":"10.13039\/100004682","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research United Kingdom","award":["C7224\/A23275"],"award-info":[{"award-number":["C7224\/A23275"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,2,6]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell responses. Radiation and drug therapies can profoundly affect the tumor immune microenvironment. Here, we aimed to identify immunotherapies to increase the antitumor response conferred by combined ataxia telangiectasia and Rad3-related kinase inhibition and radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the human papillomavirus (HPV)-negative murine oral squamous cell carcinoma model, MOC2, we assessed the nature of the antitumor response following ataxia telangiectasia and Rad3-related inhibitor (ATRi)\/radiotherapy (RT) by performing RNA sequencing and detailed flow cytometry analyses in tumors. The benefit of immunotherapies based on T cell immunoreceptor with Ig and ITIM domains (TIGIT) and Programmed cell death protein 1 (PD-1) immune checkpoint blockade following ATRi\/RT treatment was assessed in the MOC2 model and confirmed in another HPV-negative murine oral squamous cell carcinoma model called SCC7. Finally, immune profiling was performed by flow cytometry on blood samples in patients with head and neck squamous cell carcinoma enrolled in the PATRIOT clinical trial of combined ATRi\/RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ATRi enhances radiotherapy-induced inflammation in the tumor microenvironment, with natural killer (NK) cells playing a central role in maximizing treatment efficacy. We demonstrated that antitumor activity of NK cells can be further boosted with ICI targeting TIGIT and PD-1. Analyses of clinical samples from patients receiving ATRi (ceralasertib) confirm the translational potential of our preclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This work delineates a previously unrecognized role for NK cells in the antitumor immune response to radiotherapy that can be augmented by small-molecule DNA damage\u2013response inhibitors and immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-004306","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T11:50:19Z","timestamp":1647863419000},"page":"e004306","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Harnessing radiotherapy-induced NK-cell activity by combining DNA damage\u2013response inhibition and immune checkpoint blockade"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-5733","authenticated-orcid":false,"given":"Emmanuel C","family":"Patin","sequence":"first","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus T","family":"Dillon","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-3179","authenticated-orcid":false,"given":"Pablo","family":"Nenclares","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"},{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Grove","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"},{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Soliman","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Leslie","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina","family":"Northcote","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galabina","family":"Bozhanova","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Crespo-Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Baldock","sequence":"additional","affiliation":[{"name":"Biological Services Unit, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Whittock","sequence":"additional","affiliation":[{"name":"Biological Services Unit, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Baker","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Kyula","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeane","family":"Guevara","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A","family":"Melcher","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harper","sequence":"additional","affiliation":[{"name":"Early Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormas","family":"Ghadially","sequence":"additional","affiliation":[{"name":"Early Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Smith","sequence":"additional","affiliation":[{"name":"Early Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-733X","authenticated-orcid":false,"given":"Malin","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-7133","authenticated-orcid":false,"given":"Martin","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J","family":"Harrington","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"},{"name":"Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2025100314533185000_10.3.e004306.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100314533185000_10.3.e004306.2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"2025100314533185000_10.3.e004306.3","doi-asserted-by":"crossref","first-page":"S875","DOI":"10.21037\/tcr.2017.06.02","article-title":"Translational research in radiation-induced DNA damage signaling and repair","volume":"6","author":"Nickoloff","year":"2017","journal-title":"Transl Cancer Res"},{"key":"2025100314533185000_10.3.e004306.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0114-z"},{"key":"2025100314533185000_10.3.e004306.5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2025100314533185000_10.3.e004306.6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0868"},{"key":"2025100314533185000_10.3.e004306.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.014"},{"key":"2025100314533185000_10.3.e004306.8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0239"},{"key":"2025100314533185000_10.3.e004306.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature23470"},{"key":"2025100314533185000_10.3.e004306.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0246-1"},{"key":"2025100314533185000_10.3.e004306.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821"},{"key":"2025100314533185000_10.3.e004306.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96519"},{"key":"2025100314533185000_10.3.e004306.13","first-page":"16","article-title":"Patriot: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025100314533185000_10.3.e004306.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2025100314533185000_10.3.e004306.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2025100314533185000_10.3.e004306.16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"The Lancet"},{"key":"2025100314533185000_10.3.e004306.17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100314533185000_10.3.e004306.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30421-7"},{"key":"2025100314533185000_10.3.e004306.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1673"},{"key":"2025100314533185000_10.3.e004306.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2025100314533185000_10.3.e004306.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2025100314533185000_10.3.e004306.22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"2025100314533185000_10.3.e004306.23","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211"},{"key":"2025100314533185000_10.3.e004306.24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0130","article-title":"Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity","volume":"13","author":"Hou","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100314533185000_10.3.e004306.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025100314533185000_10.3.e004306.26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319"},{"key":"2025100314533185000_10.3.e004306.27","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2025100314533185000_10.3.e004306.28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"2025100314533185000_10.3.e004306.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017"},{"key":"2025100314533185000_10.3.e004306.30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638207","article-title":"Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition","volume":"8","author":"Patel","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100314533185000_10.3.e004306.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0761"},{"key":"2025100314533185000_10.3.e004306.32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340"},{"key":"2025100314533185000_10.3.e004306.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3245"},{"key":"2025100314533185000_10.3.e004306.34","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782"},{"key":"2025100314533185000_10.3.e004306.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat Commun"},{"key":"2025100314533185000_10.3.e004306.36","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0485-9"},{"key":"2025100314533185000_10.3.e004306.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1344"},{"key":"2025100314533185000_10.3.e004306.38","doi-asserted-by":"crossref","first-page":"19352","DOI":"10.1002\/jcp.28657","article-title":"Nk cells: an attractive candidate for cancer therapy","volume":"234","author":"Valipour","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025100314533185000_10.3.e004306.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2246-5"},{"key":"2025100314533185000_10.3.e004306.40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0725"},{"key":"2025100314533185000_10.3.e004306.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0"},{"key":"2025100314533185000_10.3.e004306.42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466769"},{"key":"2025100314533185000_10.3.e004306.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018"},{"key":"2025100314533185000_10.3.e004306.44","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0634-9"},{"key":"2025100314533185000_10.3.e004306.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00275","article-title":"Unleashing natural killer cells in the tumor Microenvironment-The next generation of immunotherapy?","volume":"11","author":"Ben-Shmuel","year":"2020","journal-title":"Front Immunol"},{"key":"2025100314533185000_10.3.e004306.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03231-1"},{"key":"2025100314533185000_10.3.e004306.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-303057"},{"key":"2025100314533185000_10.3.e004306.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903474106"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:53:39Z","timestamp":1759528419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-004306"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004306","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}